Treatment of Inflammatory Diseases with IL-1 Blockade

[1]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[2]  H. Nakanishi,et al.  NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy , 2017, Proceedings of the National Academy of Sciences.

[3]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[4]  L. Joosten,et al.  Uric acid priming in human monocytes is driven by the AKT–PRAS40 autophagy pathway , 2017, Proceedings of the National Academy of Sciences.

[5]  P. Mohanty,et al.  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. , 2017, The Lancet. Oncology.

[6]  E. Wirrell,et al.  Febrile infection‐related epilepsy syndrome treated with anakinra , 2016, Annals of neurology.

[7]  M. Sormani,et al.  Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. , 2016, JAMA.

[8]  G. Limongelli,et al.  Recurrent pericarditis in children and adolescents: a multicentre cohort study , 2016, Journal of cardiovascular medicine.

[9]  Scott W. Rose,et al.  Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study , 2016, Journal of cardiovascular pharmacology.

[10]  V. Pascual,et al.  Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC). , 2016 .

[11]  M. McDermott,et al.  Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. , 2016, JCI insight.

[12]  C. Dinarello,et al.  Suppression of innate inflammation and immunity by interleukin‐37 , 2016, European journal of immunology.

[13]  C. Dinarello,et al.  Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma , 2016, American journal of hematology.

[14]  D. Tousoulis,et al.  Anakinra: an emerging option for refractory idiopathic recurrent pericarditis a systematic review of published evidence , 2016, Journal of cardiovascular medicine.

[15]  M. Galeazzi,et al.  Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. , 2016, Clinical and experimental rheumatology.

[16]  Xinwei Chu,et al.  Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk , 2016, Breast Cancer Research and Treatment.

[17]  Richard L. Amdur,et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.

[18]  N. Rothwell,et al.  Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  A. Klein,et al.  The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review , 2016, Cardiology research and practice.

[20]  L. Cooper,et al.  Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis. , 2015, The American journal of cardiology.

[21]  P. Mohanty,et al.  Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer , 2015, Investigational New Drugs.

[22]  B. I. Tiftikçioğlu,et al.  IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy , 2015, Seizure.

[23]  I. Touitou,et al.  Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey , 2015, Orphanet Journal of Rare Diseases.

[24]  M. Netea,et al.  Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome , 2015, Front. Med..

[25]  M. Oosting,et al.  Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra , 2015, Annals of the rheumatic diseases.

[26]  C. Selmi,et al.  Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. , 2015, Autoimmunity reviews.

[27]  M. Senni,et al.  Successful treatment of subacute constrictive pericarditis with interleukin-1β receptor antagonist (anakinra). , 2015, Clinical and experimental rheumatology.

[28]  G. Schulert,et al.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. , 2015, Annual review of medicine.

[29]  M. Imazio.  Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options , 2014, Expert review of clinical immunology.

[30]  Nilay Kumar,et al.  Macrophage Activation Syndrome Secondary to Human Monocytic Ehrlichiosis , 2014, Indian Journal of Hematology and Blood Transfusion.

[31]  C. Stefanadis,et al.  Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases , 2014, Annals of the rheumatic diseases.

[32]  J. Lekakis,et al.  Increased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients With Coronary Artery Disease and Coexisting Rheumatoid Arthritis , 2014, Circulation. Cardiovascular imaging.

[33]  A. Martini,et al.  Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. , 2014, The Journal of pediatrics.

[34]  E. Bruera,et al.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. , 2014, The Lancet. Oncology.

[35]  D. Mikhailidis,et al.  Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors. , 2014, Journal of diabetes and its complications.

[36]  D. Maucort-Boulch,et al.  Adult-Onset Still Disease , 2014, Medicine.

[37]  J. Pickard,et al.  Recombinant Human Interleukin-1 Receptor Antagonist in Severe Traumatic Brain Injury: A Phase II Randomized Control Trial , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  J. Canada,et al.  Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? , 2014, International journal of cardiology.

[39]  N. Rothwell,et al.  The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial , 2014, Journal of Neuroinflammation.

[40]  C. Borghi,et al.  Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study , 2014, Journal of hypertension.

[41]  S. Meehan,et al.  Muckle-Wells treatment with anakinra. , 2013, Dermatology online journal.

[42]  C. Dinarello,et al.  Treating inflammation by blocking interleukin-1 in humans. , 2013, Seminars in immunology.

[43]  C. Dinarello,et al.  The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines , 2013, Front. Immunol..

[44]  G. Gardner,et al.  Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra , 2013, Arthritis care & research.

[45]  R. Unwin,et al.  The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality , 2013, BMC Nephrology.

[46]  G. Yancopoulos,et al.  Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. , 2013, Rheumatology.

[47]  G. Tuna,et al.  Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures , 2013, Seizure.

[48]  D. Foell,et al.  Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens , 2013, Arthritis Research & Therapy.

[49]  Y. Carmi,et al.  The Role of IL-1β in the Early Tumor Cell–Induced Angiogenic Response , 2013, The Journal of Immunology.

[50]  M. Camacho-Lovillo,et al.  Successful Treatment of Idiopathic Recurrent Pericarditis With Interleukin-1 Receptor Antagonist (Anakinra) , 2013, Pediatric Cardiology.

[51]  N. Voelkel,et al.  Interleukin‐1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse , 2013, Experimental physiology.

[52]  R. Terkeltaub,et al.  Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator , 2013, Arthritis Research & Therapy.

[53]  B. Cronstein,et al.  Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis , 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[54]  G. Biondi-Zoccai,et al.  Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events , 2012, BioDrugs.

[55]  P. Libby,et al.  Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial , 2012, Circulation.

[56]  James I. Clower,et al.  Rilonacept (interleukin‐1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized, double‐blind, placebo‐controlled, confirmatory efficacy study , 2012, Arthritis care & research.

[57]  C. Tsioufis,et al.  Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). , 2012, International journal of cardiology.

[58]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[59]  M. Donath,et al.  Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes , 2012, Diabetes Care.

[60]  U. Pillai,et al.  A rare case of pericarditis, complication of infliximab treatment for Crohn's disease. , 2012, Journal of Crohn's & colitis.

[61]  S. Paul,et al.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. , 2012, Arthritis and rheumatism.

[62]  N. Rothwell,et al.  Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. , 2012, Cytokine.

[63]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[64]  A. Mantovani,et al.  Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.

[65]  G. Dannecker,et al.  NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment , 2011, Arthritis research & therapy.

[66]  P. Hawkins,et al.  A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. , 2011, Journal of cardiology cases.

[67]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[68]  T. Bártfai,et al.  IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.

[69]  C. Gabel,et al.  Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity , 2011, The Journal of Biological Chemistry.

[70]  A. Simon,et al.  Hyper-IgD syndrome or mevalonate kinase deficiency , 2011, Current opinion in rheumatology.

[71]  J. Butman,et al.  Cryopyrin-Associated Periodic Syndromes , 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[72]  R. Goldbach-Mansky.  Current Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA , 2011, Current rheumatology reports.

[73]  Daniel L. Kastner,et al.  Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) , 2011, The Journal of experimental medicine.

[74]  D. Foell,et al.  Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. , 2011, Arthritis and rheumatism.

[75]  R. Cimaz,et al.  Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. , 2010, Clinical and experimental rheumatology.

[76]  N. Rothwell,et al.  Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  F. Di Virgilio,et al.  Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. , 2010, Rheumatology.

[78]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[79]  D. Kastner,et al.  Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome , 2010, Proceedings of the National Academy of Sciences.

[80]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[81]  L. Ginsberg,et al.  Neurologic manifestations of the cryopyrin-associated periodic syndrome , 2010, Neurology.

[82]  D. Kastner,et al.  Autoinflammatory Disease Reloaded: A Clinical Perspective , 2010, Cell.

[83]  G. Horneff,et al.  Rückbildung der Schwerhörigkeit bei einer Patientin mit Muckle-Wells-Syndrom unter Therapie mit Anakinra , 2010, Klinische Padiatrie.

[84]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[85]  Y. Carmi,et al.  The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis1 , 2009, The Journal of Immunology.

[86]  D. Kastner,et al.  Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy , 2009, British journal of haematology.

[87]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.

[88]  C. Gabay,et al.  Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. , 2009, Joint, bone, spine : revue du rhumatisme.

[89]  I. Andreadou,et al.  Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis , 2009, Heart.

[90]  S. Moshé,et al.  The role of interleukin-1β in febrile seizures , 2009, Brain and Development.

[91]  Seth L Masters,et al.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). , 2009, Annual review of immunology.

[92]  S. Gökben,et al.  Febrile seizures: interleukin 1beta and interleukin-1 receptor antagonist polymorphisms. , 2009, Pediatric neurology.

[93]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[94]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[95]  N. Rothwell,et al.  Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[96]  J. Berthelot,et al.  Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. , 2007, Joint, bone, spine : revue du rhumatisme.

[97]  P. Emery,et al.  Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra , 2007, Annals of the rheumatic diseases.

[98]  A. Martini,et al.  Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. , 2007, Arthritis and rheumatism.

[99]  N. Ambrose,et al.  Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis. , 2007, Clinical and experimental rheumatology.

[100]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[101]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[102]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[103]  T. Arinami,et al.  Molecular genetics of febrile seizures , 2006, Epilepsy Research.

[104]  Michael Atkins,et al.  Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[105]  Leslie L. Chavez,et al.  Topological frustration and the folding of interleukin-1 beta. , 2006, Journal of molecular biology.

[106]  P. Emery,et al.  Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism , 2006, Annals of the rheumatic diseases.

[107]  A. Dispenzieri,et al.  Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[108]  N. Rothwell,et al.  A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[109]  Y. Baysal,et al.  Interleukin-1α, Interleukin-1β, and Interleukin-1Ra Polymorphisms in Febrile Seizures , 2005 .

[110]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[111]  M. Netea,et al.  Interleukin-18 does not modulate the acute-phase response , 2005, Journal of endotoxin research.

[112]  C. Dinarello,et al.  Differences in signaling pathways by IL-1beta and IL-18. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[113]  E. Bruera,et al.  Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.

[114]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[115]  G. Hitman,et al.  Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. , 2002, Arthritis and rheumatism.

[116]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[117]  G. Fantuzzi,et al.  Effect of interleukin-18 on mouse core body temperature. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[118]  R. Kolodner,et al.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome , 2001, Nature Genetics.

[119]  D. Kastner,et al.  The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. , 2001, Blood.

[120]  A. Harken,et al.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[121]  K. Kanemoto,et al.  Interleukin (IL)‐1β, IL‐1α, and IL‐1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy , 2000 .

[122]  J. Lust,et al.  THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA , 1999 .

[123]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[124]  Ian Todd,et al.  Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.

[125]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[126]  J. V. D. van der Meer,et al.  Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. , 1996, Journal of immunology.

[127]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[128]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[129]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[130]  C. Dinarello,et al.  Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. , 1993, Blood.

[131]  D. Longo,et al.  The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin , 1993 .

[132]  A. Goldberg,et al.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. , 1983, The New England journal of medicine.

[133]  L. Buckley,et al.  Interleukin-1 blockade for the treatment of pericarditis , 2018, European heart journal. Cardiovascular pharmacotherapy.

[134]  M. Peberdy,et al.  Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study). , 2015, The American journal of cardiology.

[135]  B. Stew,et al.  Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. , 2013, B-ENT.

[136]  F. Chiarelli,et al.  Efficacy of an Interleukin-1β Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis , 2012, Pediatric Cardiology.

[137]  F. Tsai,et al.  Interleukin (IL)‐1β, IL‐1 receptor antagonist, IL‐6, IL‐8, IL‐10, and tumor necrosis factor α gene polymorphisms in patients with febrile seizures , 2010, Journal of clinical laboratory analysis.

[138]  M. McDermott,et al.  Rilonacept in the management of cryopyrin-associated periodic syndromes ( CAPS ) , 2010 .

[139]  A. So,et al.  Extended Report , 2022 .